CRS-HIPEC
PATIENT SELECTION GUIDE
CRS-HIPEC is a major operation that requires careful patient selection — the right candidate achieves meaningful survival benefit while tolerating the procedure safely. Understanding the selection criteria helps patients know whether specialist evaluation is worthwhile and what questions to ask.
analyticsAt a Glance
- check_circlePCI, completeness of cytoreduction potential, performance status, and histology are the four pillars of CRS-HIPEC selection
- check_circleCT-estimated PCI underestimates true PCI by 30–40% — diagnostic laparoscopy is the definitive eligibility assessment
- check_circleA second opinion at a specialist peritoneal oncology centre changes management in 30–40% of patients referred as 'inoperable'
- check_circleCancerFax facilitates specialist eligibility review from your existing imaging before any travel is required
Why Patient Selection Is the Most Important Step in CRS-HIPEC
CRS-HIPEC is a major abdominal operation lasting 6–14 hours with a major complication rate of 20–40% and an operative mortality of 1–5% depending on centre volume. In the wrong patient — extensive disease, aggressive histology, poor performance status — the risks of the operation can substantially outweigh any potential survival benefit. In the right patient — limited peritoneal disease, favourable histology, good performance status, achievable complete cytoreduction — CRS-HIPEC offers the only realistic chance of long-term survival.
“Good patient selection is not about gatekeeping — it is about matching the right treatment to the right patient so that the risks of a major operation are justified by the potential for meaningful, durable benefit.”
Why 'Inoperable' Often Means 'Not Evaluated by a Specialist'
Studies consistently show that 30–40% of patients told by their local team that peritoneal carcinomatosis is inoperable are reassessed as surgical candidates after specialist peritoneal oncology evaluation. Most general surgeons and oncologists have limited experience with the specific PCI thresholds and cytoreduction techniques that determine operability. A specialist second opinion is not optional — it is the standard of care.
The Four Selection Pillars
All four of these must be addressed before CRS-HIPEC is offered: (1) tumour extent — PCI and anticipated completeness of cytoreduction; (2) tumour biology — histological type and aggressiveness; (3) patient fitness — performance status and organ function; (4) oncological context — absence of unresectable extra-abdominal disease. All four must be favourable for the operation to be justified.
Universal CRS-HIPEC Selection Criteria (All Tumour Types)
The following criteria apply across all peritoneal malignancy indications — regardless of primary tumour type.
| Selection Domain | Favourable for CRS-HIPEC | Unfavourable / Contraindication |
|---|---|---|
| Peritoneal Cancer Index (PCI) | Tumour-specific thresholds: ≤20 CRC; ≤30 mesothelioma; no strict limit for PMP | PCI above indication-specific threshold with anticipated incomplete cytoreduction |
| Completeness of cytoreduction | CC-0 or CC-1 (≤2.5 mm residual) achievable — assessed at diagnostic laparoscopy | CC-2 or CC-3 anticipated — major survival benefit not established for incomplete resection |
| Extra-abdominal metastases | Absent; or limited resectable liver metastases (1–3 lesions) | Unresectable liver, lung, bone, mediastinal node, or brain metastases |
| Performance status | ECOG 0–1; WHO PS 0–2 | ECOG 3–4; WHO PS 3–5; significant cardiac (EF <40%), pulmonary (FEV1 <50% pred), or renal (GFR <50) impairment |
| Nutritional status | BMI 18.5–35; serum albumin ≥3.0 g/dL; weight-stable or improving | Severe malnutrition, cachexia, or rapid weight loss — major complication and anastomotic leak risk |
| Haematological status | Hb ≥10 g/dL; neutrophils ≥1.5 × 10⁹/L; platelets ≥100 × 10⁹/L | Significant cytopenias — correct before surgery if possible; if irreversible, re-evaluate candidacy |
| Renal function | GFR ≥50 mL/min (cisplatin HIPEC); GFR ≥40 mL/min (non-cisplatin HIPEC) | GFR <50 mL/min for cisplatin — switch to carboplatin or MMC; GFR <30 — not suitable for any HIPEC |
| Prior abdominal surgery | Prior surgery does not exclude CRS-HIPEC | Multiple prior major abdominal operations — adhesions increase complexity and anastomotic risk; discuss at specialist MDT |
| Age | No strict upper age limit — physiological age matters more than chronological | >75 years with ECOG 2 and multiple comorbidities — very careful case-by-case assessment required |
The CRS-HIPEC Evaluation Pathway
Patient selection for CRS-HIPEC follows a sequential evaluation that moves from imaging to multidisciplinary review to surgical staging.
- 1
Initial Imaging Review
CT abdomen/pelvis ± MRI peritoneal protocol ± PET-CT provides a preliminary PCI estimate, identifies extra-abdominal disease that would contraindicate surgery, and begins the risk-benefit assessment. This review should be conducted by a radiologist or surgeon familiar with peritoneal surface oncology.
- 2
Specialist Peritoneal Oncology MDT
All patients being considered for CRS-HIPEC should be reviewed at a specialist MDT that includes a peritoneal oncology surgeon, medical oncologist, interventional radiologist, and pathologist with peritoneal surface malignancy expertise. Most general oncology MDTs are not equipped to make this decision.
- 3
Performance Status and Fitness Assessment
Cardiopulmonary exercise testing (CPET), echocardiogram, and pulmonary function tests are performed to objectively measure physiological fitness for a major operation — more reliable than clinical impression alone, particularly in patients with borderline fitness.
- 4
Nutritional Optimisation
Patients with low albumin, significant weight loss, or poor nutritional status undergo a 2–4 week nutritional prehabilitation programme — oral nutritional supplements, nasogastric feeding if needed — before reassessment. Surgery is delayed until nutritional parameters are improved.
- 5
Diagnostic Laparoscopy
The definitive eligibility assessment — directly visualising all 13 peritoneal regions, measuring the largest deposit in each, and assessing small-bowel mesenteric involvement. Changes management in 30–40% of patients whose CT-based PCI suggested marginal operability.
- 6
Informed Consent and Surgery Planning
If laparoscopy confirms CC-0/1 resection is achievable, the surgeon discusses the specific procedures likely to be involved, alternative treatment options, expected outcomes from published data, and recovery timeline — obtaining fully informed consent before proceeding to CRS-HIPEC.
Selection Statistics: What the Evidence Shows
Data from specialist peritoneal oncology programmes on the impact of rigorous selection.
- 30–40%Of 'inoperable' patients reassessed as surgical candidates at specialist reviewPublished studies consistently show that 30–40% of patients referred as inoperable become surgical candidates after evaluation at a specialist peritoneal oncology centre.
- >3×Survival advantage for CC-0 vs CC-2+ resectionThe survival difference between complete cytoreduction (CC-0) and incomplete (CC-2+) in CRC peritoneal metastases exceeds a factor of three — justifying stringent selection to ensure only patients likely to achieve CC-0/1 are offered the operation.
- <2%30-day operative mortality at high-volume centresOperative mortality below 2% is achievable at centres performing >20 CRS-HIPEC cases per year with rigorous selection — emphasising why both centre volume and selection quality matter.
- 20–40%Major complication rate (Clavien-Dindo ≥3) even in selected patientsEven after optimal patient selection, CRS-HIPEC carries a 20–40% major complication rate — fully informing patients of this risk is an essential part of the consent process.
More from the Peritoneal Oncology Resource Library
Continue exploring CRS-HIPEC — from the surgery details to tumour-specific evidence and access guides.
Frequently Asked Questions
Common questions from patients assessing their CRS-HIPEC eligibility.
About Eligibility
My local oncologist said I am not a candidate because my PCI is too high — should I accept this?
Not without a specialist second opinion. PCI estimation from CT alone is imprecise — published studies show CT underestimates true surgical PCI by 30–40%. A CT-estimated PCI of 22 may be a surgical PCI of 15 at direct laparoscopy. Additionally, PCI thresholds vary by tumour type: a PCI of 25 in PMP — a slow-growing mucinous condition — is completely operable at a specialist centre, while PCI 25 in signet ring cell gastric cancer is rarely operable anywhere. Your local oncologist's PCI estimate and threshold judgement may not reflect the expertise of a specialist peritoneal oncology programme. CancerFax can arrange remote specialist imaging review from your existing CT within days.
I have already had two abdominal operations — does this disqualify me from CRS-HIPEC?
Prior abdominal surgery does not exclude CRS-HIPEC, but it significantly adds to operative complexity. Adhesions from prior surgery obscure peritoneal surfaces and increase the risk of inadvertent enterotomy (bowel injury during adhesiolysis) and anastomotic complications. At high-volume centres, surgeons with specific experience in re-do peritoneal oncology procedures — including after prior gastric, colorectal, or gynaecological surgery — manage this complexity routinely. The nature of the prior operation (laparoscopic vs open; single vs multiple; prior HIPEC) and the resulting adhesion burden are assessed at diagnostic laparoscopy before the CRS-HIPEC decision is finalised.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure If You Are a CRS-HIPEC Candidate?
CancerFax arranges specialist peritoneal oncology review of your imaging, histology, and clinical history — providing a preliminary eligibility assessment and connecting you with high-volume CRS-HIPEC surgeons in China and India for definitive staging and treatment planning.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.